Modality
Small Molecule
MOA
KRASG12Di
Target
WRN
Pathway
Tau
Alzheimer'sPBC
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
Apr 2019
→ Apr 2029
Phase 1Current
NCT04883556
2,126 pts·Alzheimer's
2019-04→2029-04·Recruiting
2,126 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-133.0y awayInterim· Alzheimer's
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Recruit…
Catalysts
Interim
2029-04-13 · 3.0y away
Alzheimer's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04883556 | Phase 1 | Alzheimer's | Recruiting | 2126 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |